Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer

Cancer Immunology, Immunotherapy

Volumn 63, Issue 3, 2014, Pages 215-224

  Maine, Christian J ^a,c   Aziz, Nor Haslinda Abdul ^b   Chatterjee, Jayanta ^b   Hayford, Claudia ^b   Brewig, Nancy ^b   Whilding, Lynsey ^b   George, Andrew J T ^a,d   Ghaem Maghami, Sadaf ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

B7 H1; IL 10; Immune regulation; Monocytes; Ovarian cancer; PD L1

Indexed keywords

ANTIBODIES, BLOCKING; ANTIGENS, CD274; CARCINOGENESIS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOSUPPRESSION; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; MOLECULAR TARGETED THERAPY; MONOCYTES; OVARIAN NEOPLASMS; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL;

EID: 84894478745     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1503-x     Document Type: Article

References (21)

1. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17):1320-1329
2. Friedlander ML (1998) Prognostic factors in ovarian cancer. Semin Oncol 25(3):305-314
3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics. CA Cancer J Clin 55(1):10-30
4. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194-3200. doi: 10.1200/JCO.2003.02.153
5. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3):203-213. doi: 10.1056/NEJMoa020177
6. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8(8):793-800. doi: 10.1038/nm730
7. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ (2007) Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27(1):111-122. doi: 10.1016/j.immuni.2007.05. 016
8. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027-1034
9. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, Tsushima F, Otsuki N, Yagita H, Azuma M, Nakajima Y (2005) Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11(8):2947-2953. doi: 10.1158/1078-0432.CCR-04-1469
10. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC, Kwon ED (2004) Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 101(49):17174-17179. doi: 10.1073/pnas.0406351101
11. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N (2006) Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 108(1):19-24. doi: 10.1016/j.acthis.2006. 01.003
12. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, Fujii S (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104(9):3360-3365. doi: 10.1073/pnas.0611533104
13. Abiko K, Mandai M, Hamanishi J, Yoshioka Y, Matsumura N, Baba T, Yamaguchi K, Murakami R, Yamamoto A, Kharma B, Kosaka K, Konishi I (2013) PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res 19(6):1363-1374. doi: 10.1158/1078-0432.CCR-12-2199
14. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow M, Gordon A, Dhurandhar N, Myers L, Berggren R, Hemminki A, Alvarez RD, Emilie D, Curiel DT, Chen L, Zou W (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9(5):562-567. doi: 10.1038/nm863
15. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455-2465. doi: 10.1056/NEJMoa1200694
16. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443-2454. doi: 10.1056/NEJMoa1200690
17. Ribas A (2012) Tumor immunotherapy directed at PD-1. N Engl J Med 366(26):2517-2519. doi: 10.1056/NEJMe1205943
18. Geng L, Jiang G, Fang Y, Dong S, Xie H, Chen Y, Shen M, Zheng S (2006) B7-H1 expression is upregulated in peripheral blood CD14 + monocytes of patients with chronic hepatitis B virus infection, which correlates with higher serum IL-10 levels. J Viral Hepat 13(11):725-733. doi: 10.1111/j.1365-2893.2006.00746. x
19. Trabattoni D, Saresella M, Biasin M, Boasso A, Piacentini L, Ferrante P, Dong H, Maserati R, Shearer GM, Chen L, Clerici M (2003) B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood 101(7):2514-2520. doi: 10.1182/blood-2002-10-3065
20. Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR, Knutson KL (2011) Tumor-infiltrating programmed death receptor-1 + dendritic cells mediate immune suppression in ovarian cancer. J Immunol 186(12):6905-6913. doi: 10.4049/jimmunol.1100274
21. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G (2013) Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 73(12):3591-3603. doi: 10.1158/0008-5472.CAN-12-4100